August 28, 2017 / 12:35 PM / 4 months ago

BRIEF-Daiichi Sankyo enters agreement with Boston Pharmaceuticals

Aug 28 (Reuters) - Daiichi Sankyo Co Ltd

* Daiichi Sankyo enters worldwide licensing agreement with Boston Pharmaceuticals for a highly selective RET inhibitor for solid tumors

* Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed

* Daiichi Sankyo Co Ltd - grants Boston Pharmaceuticals worldwide rights for research, development, manufacturing and commercialization of DS-5010 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below